BIAF Stock — bioAffinity Technologies Inc.: Cash, EV, Pipeline

Share price

$9.43

Market cap

$11.0M

Cash

$2.4M

Enterprise value

$8.9M

Balance sheet

Cash	$2.4M
Debt	$0.3M
Net cash	$2.1M
Enterprise value	$8.9M
Basic shares	6.8M shares
Fully diluted shares	12.4M shares
Fully diluted market cap	$117.0M
Cash per share	$0.36

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BIAF daily closes…

Loading price history…

Pipeline assets

Not disclosed (siRNA therapeutic)

Preclinical · Active Modality: topical siRNA (self-delivering, stabilized)

Indications

Squamous and basal cell skin cancers (Stage not disclosed)

Status note June 22, 2026: positive results from preliminary therapeutic studies showing self-delivering, stabilized siRNAs selectively kill squamous and basal carcinoma cells while leaving non-cancerous cutaneous cells unharmed. The company has no disclosed candidate name for this program. CyPath Lung (commercial lung cancer diagnostic) is not a therapeutic pipeline asset.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07168993	Not disclosed	Recruiting	Sponsor	BIAF	—	Lung Cancer (Diagnosis)	—
NCT03457415	Not disclosed	Recruiting	Sponsor	BIAF	—	Lung Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for bioAffinity Technologies Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

BIAF — bioAffinity Technologies Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials